Last Updated: November 8, 2026

Details for New Drug Application (NDA): 050779

« Back to Dashboard


NDA 050779 describes CEFAZOLIN AND DEXTROSE, which is a drug marketed by B Braun and is included in one NDA. It is available from one supplier. Additional details are available on the CEFAZOLIN AND DEXTROSE profile page.

The generic ingredient in CEFAZOLIN AND DEXTROSE is cefazolin sodium. There is one drug master file entry for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the cefazolin sodium profile page.
Summary for 050779
Tradename:CEFAZOLIN AND DEXTROSE
Applicant:B Braun
Ingredient:cefazolin sodium
Patents:0
Pharmacology for NDA: 050779
Medical Subject Heading (MeSH) Categories for 050779
Anti-Bacterial Agents
Suppliers and Packaging for NDA: 050779
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CEFAZOLIN AND DEXTROSE cefazolin sodium INJECTABLE;INJECTION 050779 NDA B. Braun Medical Inc. 0264-3103 0264-3103-11 24 CONTAINER in 1 CASE (0264-3103-11) / 50 mL in 1 CONTAINER
CEFAZOLIN AND DEXTROSE cefazolin sodium INJECTABLE;INJECTION 050779 NDA B. Braun Medical Inc. 0264-3105 0264-3105-11 24 CONTAINER in 1 CASE (0264-3105-11) / 50 mL in 1 CONTAINER

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrengthEQ 500MG BASE/VIAL
Approval Date:Jul 27, 2000TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 1GM BASE/VIAL
Approval Date:Jul 27, 2000TE:RLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 2GM BASE/VIAL
Approval Date:Jan 13, 2012TE:RLD:Yes

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links